Investigator-initiated clinical research, commonly referred to as IITs, is generally driven by scientific questions arising from clinical practice. As the conduct of IITs becomes increasingly standard...
The real dividing line in CGT research is not simply “completing administration.” It lies in what happens afterward: five years, ten years, and in some cases even lifelong follow-up.It is during thi...
In the drug development ecosystem, a long-standing “valley of death” exists between basic research discoveries and approved therapies, where many potential candidates stall due to translational barr...
Ophthalmology stands at the forefront of gene therapy translation. The retina’s immune-privileged status, anatomically confined structure, and objectively quantifiable visual endpoints have made the ...
This article examines three critical operational challenges in clinical trials for chronic ophthalmic diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (DR): patient rec...
I. Overview of Clinical Trial Endpoints for Common Ophthalmic DiseasesThe appropriate selection of endpoints in ophthalmic drug clinical trials directly determines the scientific validity of a study a...
